SUVENPHAR Suven Pharmaceuticals Ltd Earnings Calls Announcement 2025 - Earnings Call Transcript Cohance Lifesciences Ltd shared the transcript of its earnings call for Q4 FY 2025, highlighting its transformation and ambitions to reach $1 billion in revenue by 2030 with an EBITDA margin of 34%..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Suven Pharmaceuticals Ltd